Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A retrospective observational study to evaluate the risk of metachronous advanced colorectal neoplastic (ACRN) among individuals with varying numbers of non-advanced adenomas (NAA) detected during screening colonoscopy
Colorectal cancer (CRC) is the third most commonly diagnosed malignancy worldwide and the second leading cause of cancer-related mortality. In recent years, with increasing westernization of diet and lifestyle, both the incidence and prevalence of CRC in China have risen sharply. CRC has become the most common gastrointestinal malignancy in the country, ranking second in incidence and fifth in mortality among all cancers. Screening colonoscopy and appropriate surveillance intervals can substantially reduce CRC-related deaths.
The latest 2020 U.S. Multi-Society Task Force (USMSTF) guidelines classify patients with 1-2 non-advanced adenomas (NAAs), 3-4 NAAs, and >4 NAAs as having low-, intermediate-, and high-risk colonoscopic findings, respectively, and recommend surveillance intervals of 7-10 years, 3-5 years, and 3 years for these groups. However, accumulating evidence suggests that the risk of developing metachronous advanced colorectal neoplastic lesions (ACRN) in individuals with 3-4 NAAs may be comparable to those with only 1-2 NAAs, raising concerns regarding the appropriateness of current surveillance recommendations.
Using a real-world, endoscopy database, this study systematically evaluates the association between different NAA counts and the subsequent risk of ACRN, providing evidence to inform optimization of post-polypectomy surveillance intervals.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Individuals with <3 NAAs detected during screening colonoscopy | Individuals with <3 non-advanced adenomas detected during screening colonoscopy |
| |
| Individuals with 3-4 NAAs detected during screening colonoscopy | Individuals with 3-4 non-advanced adenomas detected during screening colonoscopy |
| |
| Individuals with >4 NAAs detected during screening colonoscopy | Individuals with >4 non-advanced adenomas detected during screening colonoscopy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No Intervention: Observational Cohort | Other | No Intervention: Observational Cohort |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Metachronous Advanced Colorectal Neoplasia | Metachronous advanced colorectal neoplasia is defined as advanced adenoma (≥10 mm, villous component, or high-grade dysplasia) or colorectal cancer detected at any follow-up colonoscopy after the baseline index colonoscopy. | Through study completion, an average of 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Metachronous Colorectal Neoplasia | Metachronous colorectal neoplasia is defined as any adenoma or colorectal cancer detected at any follow-up colonoscopy after the baseline index colonoscopy. | Through study completion, an average of 1 month |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Individuals who underwent their first-time screening colonoscopy between 2012 and 2023 at the endoscopy centers of Huadong Hospital and Shanghai Tongji Hospital, and who completed at least one surveillance colonoscopy.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Danian Ji, M.D. | Huadong Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Huadong hospital, Fudan university | Shanghai | Shanghai Municipality | 200040 | China |
All collected IPD
1 year after completion of this study
All researchers can require the original data from principal investigator of this study (Email address: arctg4@163.com)
Not provided
Not provided
Not provided
Not provided
Not provided